Caristo Diagnostics Showcases Innovative Research on Coronary Inflammation Technologies at SCCT 2026

Caristo Diagnostics Showcases Innovative Research at SCCT 2026

Caristo Diagnostics, a leader in AI-driven cardiovascular solutions, has announced significant findings that will be presented at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in San Diego from July 9-12, 2026. This prestigious conference will spotlight new evidence from the ORFAN registry, led by the University of Oxford. Three of the six abstracts nominated for the SCCT Young Investigator Award utilize Caristo's groundbreaking technologies, emphasizing the application of coronary inflammation and plaque analysis.

Highlighting Innovative Research

Among the standout presentations is the work led by Dr. Kenneth Chan, who will discuss how quantifying coronary inflammation using the FAI-Score on both contrast and non-contrast cardiac CT improves cardiovascular risk stratification beyond traditional metrics like the coronary calcium score and plaque volume. This advancement paves the way for more precise cardiovascular assessments that can identify patients at higher risk of adverse events, thereby informing early intervention strategies.

Another key abstract presented by Dr. Camila V. Blair, MD, will delve into the prognostic value of coronary inflammation imaging using the FAI-Score, expanding on its predictive capabilities beyond the established PREVENT score. Additionally, Ikboljon Sobirov’s presentation will explore the AI quantification of calcified and non-calcified plaques, calibrated against coronary plaque histology, showcasing its effectiveness in forecasting ten-year cardiovascular events across a substantial patient cohort.

Noteworthy Sessions

Caristo Diagnostics is set to lead discussions in multiple sessions at the conference. The "Best Original Science – Young Investigator Award Presentation Spotlight" will feature Dr. Kenneth Chan on July 11, offering insights on enhancing cardiovascular risk stratification.

Moreover, during the AI/ML Workshop, Dr. Cheerag Shirodaria will provide an overview of the integration of coronary inflammation and AI plaque analysis for comprehensive cardiovascular care—a significant upgrade in patient management techniques. There will also be a symposium focused on differentiating truly ‘low-risk’ patients from those who may appear low-risk but require closer monitoring, presented by leading experts in the field.

The Broad Impact of ORFAN Registry

The ORFAN registry, featured prominently in these discussions, is seminal in its size and scope. Having published initial findings in The Lancet in June 2024, it aims to consolidate long-term clinical and outcome data from up to 250,000 patients globally. This vast dataset is crucial for assessing imaging biomarkers like the Fat Attenuation Index (FAI) Score, which identifies cardiovascular risks linked to coronary inflammation over extended periods—up to ten years ahead of traditional assessments.

Caristo’s Mission

Caristo Diagnostics, a spin-out from the University of Oxford, is committed to enhancing cardiovascular health through early detection of heart disease. The company’s award-winning technologies, including CaRi-Plaque® and CaRi-Heart®, have received acclaim for their ability to detect hidden risks and facilitate personalized prevention strategies. Recognized as a 2026 Technology Pioneer by the World Economic Forum, Caristo aims to save lives through pioneering research applications and collaborations with leading healthcare institutions and pharmaceutical partners.

For those attending SCCT 2026, Caristo will be offering exclusive demonstrations of its innovative technologies. Interested participants can schedule an onsite demonstration or a meeting with the Caristo team at booth #100 during the conference.

As Caristo Diagnostics continues to enhance the landscape of cardiovascular diagnostics, its presence at SCCT 2026 marks a critical step in advancing the understanding of coronary inflammation and plaque analysis, ultimately contributing to better patient outcomes.